• Novo Nordisk (NYSE:NVO) has taken legal action against Hims & Hers over compounded versions of its Wegovy pill that do not have individual FDA approval.
• The FDA has moved to restrict unapproved compounded GLP-1 products, including versions referencing Wegovy, citing safety and quality concerns.
• Novo Nordisk has received FDA approval for an oral Wegovy pill for obesity and has started its commercial launch in the U.S.

Novo Nordisk, best known for its obesity and diabetes treatments, now has an oral Wegovy option alongside its injectable products. This could broaden access for patients who prefer pills over injections. At the same time, the company is pressing its case against compounded alternatives that reference its GLP-1 drugs, arguing these products bypass the full FDA approval process and could carry different safety or quality risks.

For you as an investor, this mix of legal action, regulatory support and a new product launch puts attention on how branded obesity drugs and compounded versions may coexist. The outcome of the Hims & Hers dispute, together with the FDA's stance on compounded GLP-1s, could influence pricing dynamics and prescription patterns between branded therapies like Wegovy and compounded alternatives.

Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.

For Novo Nordisk, this legal and regulatory tussle sits alongside a more difficult earnings outlook. Management is guiding for a 5% to 13% decline in 2026 sales and earnings, driven by U.S. price cuts on GLP-1 drugs, tougher payer negotiations and competition from copycat products. The lawsuit against Hims & Hers and the FDA’s tighter stance on compounded GLP-1 pills look aimed at protecting both the Wegovy franchise and the integrity of the FDA approval process at a time when pricing pressure is already front and center. Rapid early adoption of the new oral GLP-1 pill, with 170,000 patients reported within four weeks, shows clear demand for pill-based options, but it also raises questions about how much volume growth can offset lower pricing.

The Risks and Rewards Investors Should Consider

• ⚠️ Management is guiding for a 5% to 13% decline in 2026 sales and earnings because of U.S. price cuts, tougher payers and copycat competition, which could weigh on margins.
• ⚠️ The FDA has cited a Wegovy television advertisement as misleading and requested corrective action, adding regulatory scrutiny on how the new pill is promoted.
• 🎁 The FDA approval and launch of the oral Wegovy pill, plus strong early uptake, give Novo Nordisk another GLP-1 format that may support prescription volumes.
• 🎁 Legal and regulatory actions against compounded semaglutide may reduce pressure from unapproved low cost alternatives and support the position of branded GLP-1 drugs.

What To Watch Going Forward

You may want to watch how quickly oral Wegovy prescriptions build over the next few quarters, and whether that volume changes the tone of guidance around 2026 earnings pressure. The progress and outcome of the Hims & Hers lawsuit, along with any further FDA steps on compounded GLP-1 products, will be important for competitive dynamics against peers such as Eli Lilly and other obesity and diabetes drug makers. It is also worth following how Novo Nordisk updates its marketing after the FDA’s ad warning, and whether any further promotional restrictions or fines are mentioned. Finally, keep an eye on payer decisions and formulary coverage, as these will shape the balance between volume growth and pricing for Novo Nordisk’s GLP-1 portfolio.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.